Söndag 7 December | 12:17:57 Europe / Stockholm

Kalender

Est. tid*
2025-09-25 - Kvartalsrapport 2025-Q2
2025-06-16 - X-dag ordinarie utdelning EXTX 0.00 NOK
2025-06-13 - Årsstämma
2025-04-09 - Bokslutskommuniké 2024
2024-12-17 - Extra Bolagsstämma 2024
2024-09-30 - Kvartalsrapport 2024-Q2
2024-06-28 - Årsstämma
2024-06-10 - X-dag ordinarie utdelning EXTX 0.00 NOK
2024-04-18 - Bokslutskommuniké 2023
2023-09-28 - Kvartalsrapport 2023-Q2
2023-06-12 - X-dag ordinarie utdelning EXTX 0.00 NOK
2023-06-09 - Årsstämma
2023-04-21 - Bokslutskommuniké 2022
2022-09-22 - Kvartalsrapport 2022-Q2
2022-06-09 - X-dag ordinarie utdelning EXTX 0.00 NOK
2022-06-08 - Årsstämma
2022-04-27 - Bokslutskommuniké 2021
2021-08-25 - Kvartalsrapport 2021-Q2
2021-06-01 - Årsstämma
2021-05-14 - X-dag ordinarie utdelning EXTX 0.00 NOK
2021-04-29 - Bokslutskommuniké 2020
2020-07-27 - Split EXTX 1:250
2020-07-24 - Extra Bolagsstämma 2020

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har sitt huvudkontor i Oslo.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-11-24 08:25:02
24 November 2025: EXACT Therapeutics AS ("EXACT Tx" or the "Company") announces
that the Company as of today has introduced a new long-term incentive program in
the form of award of share options, each giving the right to purchase one share
in the Company at a strike price to be determined by the board of directors of
the Company, and with settlement in either shares in the Company or cash (the
"New Incentive Program"). The options will vest in tranches conditional upon the
participants continuous positions with the group, and are exercisable in
designated exercise windows, with the intention of following, inter alia, the
end of the quarter after the vesting periods. The Company wil issue a total of 1
069 643 options under the New Incentive Program.

The New Incentive Program replaces the current incentive program of the Company
(the "Current Incentive Program"). Thus, options held by certain primary
insiders of the Company under the Current Incentive Program will lapse
accordingly, while new options will be awarded to the respective participants,
including primary insiders, as further set out in the attached notifications of
trade.

This information is subject to the disclosure requirements in article 19 of the
EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading
Act.

For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of
ultrasound and microbubbles to enable targeted drug delivery in oncology.
Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to
a wide range of therapeutic agents across a multitude of indications including
within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com